Navigation Links
Promising Results in Treating Facial Bruising From Injectables
Date:9/26/2007

Top physician leading clinical trials

FREEPORT, N.Y., Sept. 26 /PRNewswire/ -- Physicians nationwide report promising results in treating facial bruising from injectable cosmetic treatments by using Pinoxide(TM), an active ingredient best known for treating under-eye circles.

Pinoxide is a proprietary blend of bicyclic monoterpene dials (BMTd) created by AGI Dermatics and formulated in the company's Remergent Microcirculation Therapy product. Pinoxide has been clinically proven to speed blood flow, warm the skin, increase resistance to cold, and reduce dark under- eye symptoms. Additional research suggests Pinoxide may also contribute to promoting firmness and resiliency in the skin. Now, physicians are studying the ingredient's ability to heal bruising.

Dr. Mark G. Rubin, a board-certified dermatologist currently practicing at the Lasky Clinic in Beverly Hills, is conducting the clinical trials on Pinoxide, applying the Microcirculation Therapy formula to the injection site immediately after use of skin fillers such as collagen, Restylane and Juvederm, or Botox.

"Anatomically speaking, dark circles are like bruises - so the science behind using Pinoxide for bruising makes total sense," said Dr. Rubin. "The skin discoloration during bruising is the result of blood leaking from damaged blood vessels and surfacing to the skin. Similarly, blood vessels under the eyes can burst, leading to the appearance of unattractive dark circles."

Leading dermatologists share Dr. Rubin's opinion. Dr. Thomas Francel, a board certified plastic surgeon, has found that application of MicroCirculation Therapy on his patients reduces the appearance of skin bruising, and decreases the amount of healing time for the bruise. Dr. Francel is the Chief of Plastic Surgery at St. John's Mercy Medical Center and an Associate Professor of Surgery at St. Louis University.

Injectable cosmetic treatments are among the five top most requested aesthetic treatments nationwide last year. According to the American Society for Aesthetic Plastic Surgery, more than 5 million women had injectable cosmetic treatments last year. Bruising is a common temporary side effect.

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Following an initial analysis, the ... Food and Drug Administration,s (FDA,s) final regulatory guidance ... by Pharmacies and Outsourcing Facilities." In its final ... pre-packaging -- which would have put patients at ... term care (LTC) pharmacies.  The ...
(Date:1/17/2017)... Research and Markets has announced the addition ... Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, ... report to their offering. ... The global active pharmaceutical ingredients market is expected ... in 2016, growing at a CAGR of 6.3% from 2016 to ...
(Date:1/17/2017)... , Jan. 17, 2017  In a preview of ... Annual Congress, Astute Medical, Inc., developer of the NephroCheck ... the test, which identifies hospital patients at risk of developing ... take place this month at the Hawaii ... January 21 through January 25. AKI is one ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... as Palm Desert, is opening a new office in San Clemente, California this ... stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased ... network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves ... exciting addition to our provider network, and the addition will benefit our members ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... ... 17, 2017 , ... SC&H Group, a leading audit, tax, and consulting firm, ... IT Advisory Services practice . Rossi is the third technology consulting leader to join ... guidance grows, and the practice continues to expand.     , Bringing more than 25 years ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
Breaking Medicine News(10 mins):